Veradermics Prices Upsized IPO at $17 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy ?
Source: Businesswire
- Upsized IPO Announcement: Veradermics has priced its upsized initial public offering at $17.00 per share for 15,077,647 shares, expecting gross proceeds of approximately $256.3 million, reflecting strong market demand for its innovative therapeutic products.
- Exchange Listing Plans: The company's stock is set to begin trading on the New York Stock Exchange on February 4, 2026, under the ticker symbol “MANE”, marking a significant step in its capital market journey that could enhance brand visibility and investor confidence.
- Underwriter Selection: Jefferies, Leerink Partners, Citigroup, and Cantor have been appointed as joint book-running managers for the IPO, indicating robust professional support in financing efforts, which bolsters investor trust in the offering.
- Additional Share Option: Veradermics has granted underwriters a 30-day option to purchase an additional 2,261,647 shares at the IPO price, further enhancing its financing flexibility and market appeal.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
